Lipid mass spectrometry
From LipidomicsWiki
(Difference between revisions)
| Line 20: | Line 20: | ||
* [[Lysophosphatidylcholine - ESI-MS/MS - Liebisch et al.]] | * [[Lysophosphatidylcholine - ESI-MS/MS - Liebisch et al.]] | ||
* [[Phosphatidylcholine / Sphingomyelin - ESI-MS/MS - Liebisch et al.]] | * [[Phosphatidylcholine / Sphingomyelin - ESI-MS/MS - Liebisch et al.]] | ||
| + | * [[Phosphatidylethanolamine - ESI-MS/MS - Liebisch et al.]] | ||
| + | * [[Phosphatidylethanolamine-based plasmalogens - ESI-MS/MS - Liebisch et al.]] | ||
| + | * [[Phosphatidylethanolserine - ESI-MS/MS - Liebisch et al.]] | ||
* [[Sphingosine-1-phosphate - LC-MS/MS - Berdyshev et al.]] | * [[Sphingosine-1-phosphate - LC-MS/MS - Berdyshev et al.]] | ||
* [[Sphingosine-1-phosphate - LC-MS/MS - Bielawski et al.]] | * [[Sphingosine-1-phosphate - LC-MS/MS - Bielawski et al.]] | ||
| Line 63: | Line 66: | ||
|content= | |content= | ||
<div style="height: 150px; width: 100%; overflow: auto; padding-left: 0px; margin-top: 5px; text-align: left; border:solid 0px #CCCCCC;" title="braglist - zum scrollen"; > | <div style="height: 150px; width: 100%; overflow: auto; padding-left: 0px; margin-top: 5px; text-align: left; border:solid 0px #CCCCCC;" title="braglist - zum scrollen"; > | ||
| + | * '''28 July 2008:''' [[Phosphatidylethanolamine - ESI-MS/MS - Liebisch et al.]] | ||
| + | * '''28 July 2008:''' [[Phosphatidylethanolamine-based plasmalogens - ESI-MS/MS - Liebisch et al.]] | ||
| + | * '''28 July 2008:''' [[Phosphatidylethanolserine - ESI-MS/MS - Liebisch et al.]] | ||
* '''28 July 2008:''' [[Sphingosine-1-phosphate - LC-MS/MS - Bielawski et al.]] | * '''28 July 2008:''' [[Sphingosine-1-phosphate - LC-MS/MS - Bielawski et al.]] | ||
* '''25 July 2008:''' [[Cholesterol / Cholesterylester - ESI-MS/MS - Liebisch et al.]] | * '''25 July 2008:''' [[Cholesterol / Cholesterylester - ESI-MS/MS - Liebisch et al.]] | ||
Revision as of 17:37, 28 July 2008
Discussion forum for mass spectrometric and chromatographic methods of molecular lipid species managed by Task Force I in the LipidomicNet (EU-Framework VII Program).
